Geneoscopy
Develops non-invasive, stool-based RNA tests to detect colorectal cancer and precancerous lesions.
What they do
Geneoscopy designs non-invasive screening diagnostics utilizing eukaryotic RNA biomarkers isolated from stool samples. Clinicians and gastroenterologists use its ColoSense test to detect colorectal cancer and high-risk adenomas early, avoiding or prioritizing subsequent colonoscopy screening procedures.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- St. Louis, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $115M raised
Notable investors: Lightstone Ventures, Sect-37, Cultivation Capital, RiverVest Venture Partners.